KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer

May 29-June 2, 2015; Chicago, Illinois
Median overall survival was 11 months, with a median duration of response of 40 weeks with pembrolizumab in PD-L1–positive gastric cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 624 KB
Released: June 2, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Latest data on nivolumab plus chemotherapy or ipilimumab for untreated advanced esophageal cancer (CheckMate 648) from ASCO 2021 reported by Clinical Care Options (CCO)

Released: June 11, 2021

Data from ASCO 2021 on the CheckMate 649 trial of first-line nivolumab + chemotherapy for gastroesophageal cancer, as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Get a preview of key studies being presented at ASCO 2021 from experts in solid tumors and hematologic malignancies from Clinical Care Options (CCO)

person default Angeles Alvarez Secord, MD Michael A. Davies, MD, PhD Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Evan J. Lipson, MD Joyce O'Shaughnessy, MD Daniel P. Petrylak, MD Zofia Piotrowska, MD, MHS Elizabeth R. Plimack, MD, MS Karen L. Reckamp, MD, MS Manish A. Shah, MD Eunice S. Wang, MD Released: June 2, 2021

Expert video on new and established therapies targeting HER2/HER3 in gastrointestinal cancers, from Clinical Care Options (CCO)

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Daniel Catenacci, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.5 Medical Knowledge MOC point(s) Released: May 27, 2021 Expired: May 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue